Yes. Taking the pill with a meal or a full glass of water can reduce the likelihood of stomach upset.
Etoricoxib selectively inhibits COX-2, whereas traditional NSAIDs block both COX-1 and COX-2, which can lead to higher rates of gastrointestinal irritation.
Long-term therapy may increase cardiovascular and renal risks; regular monitoring of blood pressure, kidney function, and liver enzymes is recommended.
Moderate alcohol consumption can heighten gastrointestinal bleeding risk; it is advisable to limit intake and discuss with your prescriber.
Both are COX-2 selective, but dosing strengths, pharmacokinetic profiles, and regulatory approvals differ. Clinical choice depends on individual response and safety considerations.
Take the missed dose as soon as you remember, unless it is close to the time for your next dose. Do not double-dose.
Store at room temperature, away from moisture and direct sunlight, and keep the container tightly closed.
It is generally avoided, especially in the third trimester, due to potential risks to the fetus. Use only if the benefit clearly outweighs the risk and under medical supervision.
Symptoms may include rash, itching, swelling of the face or throat, and difficulty breathing. Seek emergency medical care immediately if they occur.
It can modestly elevate liver enzymes and may interfere with certain clotting tests if taken with anticoagulants. Inform your laboratory of all medications before testing.
Etoricoxib is a prescription medication classified as a selective cyclo-oxygenase-2 (COX-2) inhibitor, belonging to the broader family of non-steroidal anti-inflammatory drugs (NSAIDs). It is marketed in pill form and is available in strengths of 60 mg, 90 mg, and 120 mg. In Hong Kong, Etoricoxib is regulated by the Department of Health and may be prescribed by licensed healthcare providers for approved pain-relief indications.
Etoricoxib selectively blocks the COX-2 enzyme, which is primarily responsible for converting arachidonic acid into prostaglandins that mediate inflammation, pain, and fever. By inhibiting COX-2 while largely sparing COX-1, Etoricoxib reduces the production of pain-inducing prostaglandins at sites of inflammation, leading to decreased swelling and discomfort. The drug is absorbed after oral ingestion, reaches peak plasma concentrations within 1-2 hours, and has an elimination half-life of roughly 22 hours, supporting once-daily dosing for many patients.
Etoricoxib is approved in Hong Kong for the following indications:
These uses are based on clinical evidence that COX-2 inhibition effectively controls inflammatory pain in musculoskeletal and crystal-induced arthritis. The medication is intended for adult patients; pediatric use is not approved.
Evidence from peer-reviewed studies suggests that COX-2 selective inhibitors, including Etoricoxib, may provide analgesia in certain chronic pain conditions such as low-back pain or dysmenorrhea. However, these uses are not approved by Hong Kong regulatory authorities.
Disclaimer: Off-label use requires careful medical supervision and individualized risk assessment.
Ideal candidates are adults requiring anti-inflammatory pain relief who have no contraindications listed below.
Absolute contraindications
Relative contraindications
Special populations
When uncertainties exist, clinicians typically assess overall cardiovascular risk, renal function, and gastrointestinal history before prescribing Etoricoxib.
These effects are usually transient and may improve with food or dose adjustment.
Any of these symptoms warrant immediate medical attention.
Etoricoxib is metabolized partly by CYP3A4; strong inhibitors (e.g., ketoconazole) can raise drug levels, while inducers (e.g., rifampin) may lower efficacy.
Standard dosing:
60 mg once daily for mild to moderate pain (e.g., osteoarthritis).
90 mg once daily for moderate to severe pain (e.g., rheumatoid arthritis).
120 mg once daily for acute gout flares or short-term post-operative pain.
Administration: Swallow the pill whole with water; do not crush or chew.
Special populations:
Renal impairment: Dose may be reduced; follow prescriber guidance.
Elderly: Begin with the lowest effective dose (often 60 mg).
Missed dose: Take it as soon as remembered unless it is near the time of the next scheduled dose; do not double.
Overdose: Symptoms may include nausea, vomiting, stomach pain, and dizziness. Seek emergency care; supportive measures are the mainstay of treatment.
Discontinuation: Etoricoxib does not usually require tapering, but abrupt cessation after prolonged high-dose therapy should be discussed with a clinician to monitor for rebound pain.
If dosing uncertainties arise, clinicians individualize regimens based on pain severity, comorbidities, and response.
Patients on Etoricoxib should have periodic assessments, especially when therapy exceeds three months:
Any abnormal findings should prompt dose reassessment or alternative therapy.
This article provides educational information about Etoricoxib and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
